ABSTRACT
Key Concepts ......................................................................................................... 144 Introduction ............................................................................................................ 144 PGx Biomarkers for Toxicities Associated with Cancer Therapy .......................... 146 Patient Case 1 ......................................................................................................... 153
UGT1A1 and Irinotecan .................................................................................... 153 Patient Case 2 ......................................................................................................... 157
TPMT Polymorphisms and 6-MP...................................................................... 157 TPMT Polymorphisms and Cisplatin ................................................................ 158
Patient Case 3 ......................................................................................................... 159 Dihydropyrimidine and 5-FU ............................................................................ 159 CYP PGx ........................................................................................................... 160
Patient Case 4 ......................................................................................................... 161 G6PD and Rasburicase and Dabrafenib ............................................................ 162 Drug Transporter-Related Biomarkers ............................................................. 162
Patient Case 5 ......................................................................................................... 163 Drug Target-Related Biomarkers ...................................................................... 163 HER2 Blocking Monoclonal Antibody and Breast Cancer............................... 163
Patient Case 6 ......................................................................................................... 165 ER/PR Receptors ............................................................................................... 166
Patient Case 7 ......................................................................................................... 166 EGFR Antagonist and Targeted Therapy for Cancer ........................................ 167
Cetuximab and Panitumumab ................................................................................ 168 Crizotinib and Ceritinib ......................................................................................... 169 A New Generation of the BCR-ABL TKIs ............................................................ 170 BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations ............... 171
MEK Inhibitor Trametinib ................................................................................ 172 PD-1 Inhibitors .................................................................................................. 172 Others ................................................................................................................ 172
Conclusions and Future Perspectives ..................................................................... 173 Study Questions ..................................................................................................... 173 References .............................................................................................................. 175
• Better management of cancer patients is a big challenge clinicians have to face in patient care as many cancer chemotherapies are associated with severe drug toxicities. For these patients, these toxicities may affect their quality of life and also impair their adherence to subsequent therapy.
